Gilead Churns Out Additional Trodelvy Data

• Gilead Sciences Inc (NASDAQ: GILD) announced new data from the Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or more prior systemic therapies.

• The results were presented at the European Society of Medical Oncology (ESMO21) Congress 2021.

• The Company said that a sub-analysis from the study showed significant and clinically meaningful improvements in health-related quality of life over the standard of care (SoC).

• Trodelvy received full FDA approval in April to treat metastatic TNBC patients in the second-line or later, in addition to an accelerated OK in urothelial carcinoma the same month.

• Related Content: Gilead's Trodelvy Wins FDA Regular Approval For Triple-Negative Breast Cancer.

• Among the group of 419 total patients, the 236 who were in the drug arm showed significant and clinically meaningful improvements across the board.

• Trodelvy patients saw improvements in global health status, physical functioning, and emotional functioning, compared to those who received SoC of physician's chemotherapy choice.

• Gilead also said it observed significant improvements in symptomatic impact of fatigue, pain, difficulty breathing, and insomnia.

• Only diarrhea was significantly and meaningfully worse with Trodelvy.

• Price Action: GILD stock is down 0.68% at $71.27 during the market session on the last check Thursday.

• Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)

See more from Benzinga

• Click here for options trades from Benzinga

• AbbVie Submits Upadacitinib Applications In US, Europe For Ulcerative Colitis

• BeyondSpring Presents New Plinabulin Data At ESMO Congress

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.